NCT01121991View on ClinicalTrials.gov

A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2005

Conditions

InfertilityOvarian Stimulation

Interventions

DRUG

Recombinant Human-Luteinizing Hormone (Luveris)

Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.